Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806195 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,744
- Enrollment target
NCT00806195 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 7,744 participants.
The verdict
NCT00806195, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,744 participants
- Enrollment target
Study Summary
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
Interventions
- BIOLOGICAL MenACWY-CRM197
- BIOLOGICAL DTaP (Diptheria, Tetanus, Pertussis) Vaccine
- BIOLOGICAL Hib (Haemophilus influenza b) Vaccine
- BIOLOGICAL IPV (Inactivated Polio Vaccine) Vaccine
- BIOLOGICAL Pneumococcal conjugate Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,744 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806195
The ClinicalTrials.gov registry entry for NCT00806195 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,744 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MenACWY-CRM197 is the first listed.
NCT00806195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806195 about?
NCT00806195 is a clinical study titled "Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants". The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
What is the current status of trial NCT00806195?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,744 participants. The study started on 2008-12. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00806195?
The interventions under investigation include: MenACWY-CRM197 (BIOLOGICAL), DTaP (Diptheria, Tetanus, Pertussis) Vaccine (BIOLOGICAL), Hib (Haemophilus influenza b) Vaccine (BIOLOGICAL), IPV (Inactivated Polio Vaccine) Vaccine (BIOLOGICAL), Pneumococcal conjugate Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00806195?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.